Published in J Immunol on March 01, 1990
Suppressor T cells generated by oral tolerization to myelin basic protein suppress both in vitro and in vivo immune responses by the release of transforming growth factor beta after antigen-specific triggering. Proc Natl Acad Sci U S A (1992) 4.94
Suppression of diabetes in nonobese diabetic mice by oral administration of porcine insulin. Proc Natl Acad Sci U S A (1991) 2.72
Experimental granulomatous colitis in mice is abrogated by induction of TGF-beta-mediated oral tolerance. J Exp Med (1996) 2.68
Antigen-driven bystander suppression after oral administration of antigens. J Exp Med (1991) 2.62
Induction of circulating myelin basic protein and proteolipid protein-specific transforming growth factor-beta1-secreting Th3 T cells by oral administration of myelin in multiple sclerosis patients. J Clin Invest (1996) 2.27
Vaccination strategies for mucosal immune responses. Clin Microbiol Rev (2001) 1.98
Cholera toxin B subunit: an efficient transmucosal carrier-delivery system for induction of peripheral immunological tolerance. Proc Natl Acad Sci U S A (1994) 1.66
Oral immunisation as a strategy for enhancing corneal allograft survival. Br J Ophthalmol (1997) 1.51
A cholera toxoid-insulin conjugate as an oral vaccine against spontaneous autoimmune diabetes. Proc Natl Acad Sci U S A (1997) 1.40
Treatment of experimental autoimmune encephalomyelitis by feeding myelin basic protein conjugated to cholera toxin B subunit. Proc Natl Acad Sci U S A (1996) 1.38
Mucosal tolerance and suppression of collagen-induced arthritis (CIA) induced by nasal inhalation of synthetic peptide 184-198 of bovine type II collagen (CII) expressing a dominant T cell epitope. Clin Exp Immunol (1996) 1.27
Nasal administration of retinal antigens suppresses the inflammatory response in experimental allergic uveoretinitis. A preliminary report of intranasal induction of tolerance with retinal antigens. Br J Ophthalmol (1993) 1.21
Oral tolerance in disease. Gut (1999) 1.17
Oral tolerization with peptide 336-351 linked to cholera toxin B subunit in preventing relapses of uveitis in Behcet's disease. Clin Exp Immunol (2004) 1.16
Oral tolerance. J Clin Immunol (1998) 1.11
Peptide-induced nasal tolerance for a mycobacterial heat shock protein 60 T cell epitope in rats suppresses both adjuvant arthritis and nonmicrobially induced experimental arthritis. Proc Natl Acad Sci U S A (1997) 1.10
Induction of immunity and oral tolerance with polymorphic class II major histocompatibility complex allopeptides in the rat. Proc Natl Acad Sci U S A (1992) 1.10
Intranasal administration of retinal antigens suppresses retinal antigen-induced experimental autoimmune uveoretinitis. Immunology (1994) 1.10
Antigen-specific immunotherapy: is it a real possibility to combat T-cell-mediated autoimmunity? Proc Natl Acad Sci U S A (1994) 1.08
Prevention of pristane-induced arthritis by the oral administration of type II collagen. Immunology (1993) 1.05
Interleukin-2 treatment potentiates induction of oral tolerance in a murine model of autoimmunity. J Clin Invest (1994) 1.00
Experimental autoimmune uveoretinitis (EAU) versus experimental allergic encephalomyelitis (EAE): a comparison of T cell-mediated mechanisms. Clin Exp Immunol (1992) 0.88
Suppression of ongoing experimental myasthenia by oral treatment with an acetylcholine receptor recombinant fragment. J Clin Invest (1999) 0.87
Experimental approaches to specific immunotherapies in autoimmune disease: future treatment of endogenous posterior uveitis? Br J Ophthalmol (1995) 0.86
Total dose and frequency of administration critically affect success of nasal mucosal tolerance induction. Br J Ophthalmol (2001) 0.85
Modulating phenotype and cytokine production of leucocytic retinal infiltrate in experimental autoimmune uveoretinitis following intranasal tolerance induction with retinal antigens. Br J Ophthalmol (1999) 0.83
Oral desensitisation in rheumatoid arthritis. Ann Rheum Dis (1994) 0.82
Prevention of experimental autoimmune uveoretinitis and experimental autoimmune pinealitis in (Lewis x Brown-Norway) F1 rats by HgCl2 injections. Immunology (1991) 0.81
Interphotoreceptor retinoid binding protein is a potent tolerogen in Lewis rat: suppression of experimental autoimmune uveoretinitis is retinal antigen specific. Br J Ophthalmol (1997) 0.80
Therapeutic advances in immunosuppression. Clin Exp Immunol (1994) 0.79
Ocular surface epithelium induces expression of human mucosal lymphocyte antigen (HML-1) on peripheral blood lymphocytes. Br J Ophthalmol (2004) 0.79
Suppression of actively induced experimental autoimmune uveoretinitis by CD4+ T cells. Graefes Arch Clin Exp Ophthalmol (1997) 0.79
Oral tolerance to cancer can be abrogated by T regulatory cell inhibition. PLoS One (2014) 0.78
Maturation-resistant dendritic cells ameliorate experimental autoimmune uveoretinitis. Immune Netw (2011) 0.77
Single dose intranasal administration of retinal autoantigen generates a rapid accumulation and cell activation in draining lymph node and spleen: implications for tolerance therapy. Br J Ophthalmol (2001) 0.77
Suppression of induction of experimental immune mediated blepharoconjunctivitis by tolerogenic conjugates of the antigen and monomethoxypolyethylene glycol. Br J Ophthalmol (1999) 0.75
Orally tolerant CD4 T cells respond poorly to antigenic stimulation but strongly to direct stimulation of intracellular signaling pathways. Cytotechnology (2001) 0.75
A bird in the hand. Br J Ophthalmol (2002) 0.75
Lymphocyte subsets in conjunctival mucosa-associated-lymphoid-tissue after exposure to retinal-S-antigen. Int Ophthalmol (1999) 0.75
Regulatory T cell clones induced by oral tolerance: suppression of autoimmune encephalomyelitis. Science (1994) 8.69
Dependence of human stem cell engraftment and repopulation of NOD/SCID mice on CXCR4. Science (1999) 8.43
Increased insulin sensitivity and obesity resistance in mice lacking the protein tyrosine phosphatase-1B gene. Science (1999) 7.84
B7-1 and B7-2 costimulatory molecules activate differentially the Th1/Th2 developmental pathways: application to autoimmune disease therapy. Cell (1995) 6.88
Suppressor T cells generated by oral tolerization to myelin basic protein suppress both in vitro and in vivo immune responses by the release of transforming growth factor beta after antigen-specific triggering. Proc Natl Acad Sci U S A (1992) 4.94
T-cell recognition of an immunodominant myelin basic protein epitope in multiple sclerosis. Nature (1990) 4.40
Molecular basis of reovirus virulence: role of the S1 gene. Proc Natl Acad Sci U S A (1977) 3.97
Activation of CD25(+)CD4(+) regulatory T cells by oral antigen administration. J Immunol (2001) 3.86
Standardization of vitreal inflammatory activity in intermediate and posterior uveitis. Ophthalmology (1985) 3.83
Vaccination with a recombinant vaccinia virus encoding a "self" antigen induces autoimmune vitiligo and tumor cell destruction in mice: requirement for CD4(+) T lymphocytes. Proc Natl Acad Sci U S A (1999) 3.66
Peripheral deletion of antigen-reactive T cells in oral tolerance. Nature (1995) 3.46
Effects of oral administration of type II collagen on rheumatoid arthritis. Science (1993) 3.32
Absolute linkage of virulence and central nervous system cell tropism of reoviruses to viral hemagglutinin. J Infect Dis (1980) 3.27
Resistance to experimental autoimmune encephalomyelitis in mice lacking the CC chemokine receptor (CCR)2. J Exp Med (2000) 3.15
CCR5(+) and CXCR3(+) T cells are increased in multiple sclerosis and their ligands MIP-1alpha and IP-10 are expressed in demyelinating brain lesions. Proc Natl Acad Sci U S A (1999) 3.07
IL-10 is critical in the regulation of autoimmune encephalomyelitis as demonstrated by studies of IL-10- and IL-4-deficient and transgenic mice. J Immunol (1998) 2.93
Intensive immunosuppression in progressive multiple sclerosis. A randomized, three-arm study of high-dose intravenous cyclophosphamide, plasma exchange, and ACTH. N Engl J Med (1983) 2.93
Shared human T cell receptor V beta usage to immunodominant regions of myelin basic protein. Science (1990) 2.86
Induction of anergy or active suppression following oral tolerance is determined by antigen dosage. Proc Natl Acad Sci U S A (1994) 2.82
Suppression of diabetes in nonobese diabetic mice by oral administration of porcine insulin. Proc Natl Acad Sci U S A (1991) 2.72
A new model of autoimmune disease. Experimental autoimmune uveoretinitis induced in mice with two different retinal antigens. J Immunol (1988) 2.68
Antigen-driven bystander suppression after oral administration of antigens. J Exp Med (1991) 2.62
Suppression of experimental autoimmune encephalomyelitis by oral administration of myelin basic protein and its fragments. J Immunol (1988) 2.59
Seasonal prevalence of MS disease activity. Neurology (2010) 2.59
T cell lines mediating experimental autoimmune uveoretinitis (EAU) in the rat. J Immunol (1986) 2.55
Neutralization of reovirus: the gene responsible for the neutralization antigen. J Exp Med (1977) 2.53
Comparison of invasive and noninvasive tests for detecting Helicobacter pylori infection in bleeding peptic ulcers. Gastrointest Endosc (1999) 2.51
Increased frequency of interleukin 2-responsive T cells specific for myelin basic protein and proteolipid protein in peripheral blood and cerebrospinal fluid of patients with multiple sclerosis. J Exp Med (1994) 2.45
Conjunctival lesions in adults. A clinical and histopathologic review. Cornea (1987) 2.43
Disease steps in multiple sclerosis: a simple approach to evaluate disease progression. Neurology (1995) 2.42
Disease steps in multiple sclerosis: a longitudinal study comparing disease steps and EDSS to evaluate disease progression. Mult Scler (1999) 2.35
Cyclosporin A therapy in the treatment of intraocular inflammatory disease resistant to systemic corticosteroids and cytotoxic agents. Am J Ophthalmol (1983) 2.30
HLA B*44: protective effects in MS susceptibility and MRI outcome measures. Neurology (2010) 2.29
Identification of the gene coding for the hemagglutinin of reovirus. Virology (1978) 2.28
Induction of circulating myelin basic protein and proteolipid protein-specific transforming growth factor-beta1-secreting Th3 T cells by oral administration of myelin in multiple sclerosis patients. J Clin Invest (1996) 2.27
In vivo activated T lymphocytes in the peripheral blood and cerebrospinal fluid of patients with multiple sclerosis. N Engl J Med (1985) 2.27
Loss of suppressor T cells in active multiple sclerosis. Analysis with monoclonal antibodies. N Engl J Med (1980) 2.21
Ophthalmic involvement in acquired immunodeficiency syndrome. Ophthalmology (1984) 2.12
Intraocular lymphoma. Clinical and histopathologic diagnosis. Ophthalmology (1993) 2.10
Suppression of adjuvant arthritis in Lewis rats by oral administration of type II collagen. J Immunol (1990) 2.09
Characterization of biologically active antineutrophil cytoplasmic antibodies induced in mice. Pathogenetic role in experimental vasculitis. Arthritis Rheum (1995) 2.09
Oral tolerance in myelin basic protein T-cell receptor transgenic mice: suppression of autoimmune encephalomyelitis and dose-dependent induction of regulatory cells. Proc Natl Acad Sci U S A (1996) 2.06
Surgery for angiographically occult cerebral aneurysms. J Neurosurg (1993) 2.06
Interaction of reovirus with cell surface receptors. I. Murine and human lymphocytes have a receptor for the hemagglutinin of reovirus type 3. J Immunol (1980) 2.06
Immunohistochemical analysis of the cellular infiltrate in multiple sclerosis lesions. Ann Neurol (1986) 2.06
Central retinal vein occlusion: a prospective histopathologic study of 29 eyes in 28 cases. Retina (1981) 2.05
T-cell recognition of myelin basic protein. Immunol Today (1991) 1.98
Increased interleukin 12 production in progressive multiple sclerosis: induction by activated CD4+ T cells via CD40 ligand. Proc Natl Acad Sci U S A (1997) 1.95
A monoclonal antibody against a myelin oligodendrocyte glycoprotein induces relapses and demyelination in central nervous system autoimmune disease. J Immunol (1987) 1.92
Upregulation of vascular endothelial growth factor in ischemic and non-ischemic human and experimental retinal disease. Histol Histopathol (1997) 1.90
Common T-cell receptor V beta usage in oligoclonal T lymphocytes derived from cerebrospinal fluid and blood of patients with multiple sclerosis. Ann Neurol (1991) 1.85
Expression of heparanase by platelets and circulating cells of the immune system: possible involvement in diapedesis and extravasation. Invasion Metastasis (1992) 1.79
Induction of partial immune tolerance to factor VIII through prior mucosal exposure to the factor VIII C2 domain. J Thromb Haemost (2006) 1.75
Natalizumab treatment is associated with peripheral sequestration of proinflammatory T cells. Neurology (2009) 1.73
Monoclonal antibody identification of a 100-kDa membrane protein in HeLa cells and human spinal cord involved in poliovirus attachment. Proc Natl Acad Sci U S A (1988) 1.73
Pathology of experimental autoimmune uveoretinitis in mice. J Autoimmun (1990) 1.71
Treatment of uveitis by oral administration of retinal antigens: results of a phase I/II randomized masked trial. Am J Ophthalmol (1997) 1.71
Clinical biochemical and pathologic correlations in Bietti's crystalline dystrophy. Am J Ophthalmol (1994) 1.70
Interleukin 12 protects from a T helper type 1-mediated autoimmune disease, experimental autoimmune uveitis, through a mechanism involving interferon gamma, nitric oxide, and apoptosis. J Exp Med (1999) 1.70
Identification of a new epitope of human IRBP that induces autoimmune uveoretinitis in mice of the H-2b haplotype. Invest Ophthalmol Vis Sci (2000) 1.68
IFN-gamma-deficient mice develop experimental autoimmune uveitis in the context of a deviant effector response. J Immunol (1997) 1.68
Antigen microarrays identify CNS-produced autoantibodies in RRMS. Neurology (2012) 1.67
Primary intraocular lymphoma diagnosed by fine needle aspiration biopsy of a subretinal lesion. Retina (2001) 1.67
Oral tolerance: mechanisms and therapeutic applications. Adv Immunol (1999) 1.65
Etoricoxib (MK-0663): preclinical profile and comparison with other agents that selectively inhibit cyclooxygenase-2. J Pharmacol Exp Ther (2001) 1.65
Identification of a hemagglutinin-specific idiotype associated with reovirus recognition shared by lymphoid and neural cells. J Exp Med (1982) 1.64
Low-dose low-molecular-weight heparin (enoxaparin) is beneficial in lichen planus: a preliminary report. J Am Acad Dermatol (1998) 1.64
Extracellular matrix moieties, cytokines, and enzymes: dynamic effects on immune cell behavior and inflammation. J Leukoc Biol (2000) 1.64
The cell-binding domain of intimin from enteropathogenic Escherichia coli binds to beta1 integrins. J Biol Chem (1996) 1.64
Induction of oral tolerance to myelin basic protein in CD8-depleted mice: both CD4+ and CD8+ cells mediate active suppression. J Immunol (1995) 1.63
Structural abnormalities develop in the brain after ablation of the gene encoding nonmuscle myosin II-B heavy chain. J Comp Neurol (2001) 1.63
The mucosal milieu creates tolerogenic dendritic cells and T(R)1 and T(H)3 regulatory cells. Nat Immunol (2001) 1.63
Respiratory symptoms of primary school children living in a petrochemical polluted area in Taiwan. Pediatr Pulmonol (1998) 1.61
Immunohistologic findings and results of treatment with cyclosporine in ligneous conjunctivitis. Am J Ophthalmol (1989) 1.57
The role of apoptosis in the pathogenesis of Fuchs endothelial dystrophy of the cornea. Arch Ophthalmol (2001) 1.56
Quinolines as potent 5-lipoxygenase inhibitors: synthesis and biological profile of L-746,530. Bioorg Med Chem Lett (1998) 1.54
Endogenous systemic IFN-gamma has a protective role against ocular autoimmunity in mice. J Immunol (1994) 1.53
Case report: portal vein thrombosis associated with hereditary protein C deficiency: a report of two cases. J Gastroenterol Hepatol (1999) 1.52
Central retinal vein occlusion: a prospective histopathologic study of 29 eyes in 28 cases. Trans Am Ophthalmol Soc (1981) 1.52
Extracellular K(+) and opening of voltage-gated potassium channels activate T cell integrin function: physical and functional association between Kv1.3 channels and beta1 integrins. J Exp Med (2000) 1.52
Primary intraocular lymphoma with a low interleukin 10 to interleukin 6 ratio and heterogeneous IgH gene rearrangement. Arch Ophthalmol (1999) 1.52
Immune response in subacute sclerosing panencephalitis: reduced antibody response to the matrix protein of measles virus. J Immunol (1979) 1.52
Oligoclonal T lymphocytes in the cerebrospinal fluid of patients with multiple sclerosis. J Exp Med (1988) 1.52
Generation of cytolytic T lymphocytes after reovirus infection: role of S1 gene. Proc Natl Acad Sci U S A (1979) 1.50
Organizational characteristics and information content of an archaeal genome: 156 kb of sequence from Sulfolobus solfataricus P2. Mol Microbiol (1996) 1.49
Effectiveness of cyclosporin therapy for Behçet's disease. Arthritis Rheum (1985) 1.49
Neuroimmunology I: Immunoregulation in neurological disease. Ann Neurol (1982) 1.48
MS: a CNS and systemic autoimmune disease. Immunol Today (1989) 1.47